Market Overview

UPDATE: Citigroup Initiates Coverage on Teva Pharmaceutical Industries Ltd. on Attractive Risk-Reward Profile

Share:
Related TEVA
Mylan Confirms USPTO Institutes Inter Partes Review Proceedings vs Two Copaxone 40 mg/mL Dosing Patents
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
Eli Lilly's Alimta Patent Upheld by U.S. District Court (Zacks)

In a report published Friday, Citigroup analyst Liav Abraham initiated coverage on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) with a Buy rating and $47.00 price target.

In the report, Citigroup noted, “We see the potential for value to be unlocked over the next 12 months as investors look past the Copaxone cliff, and focus on the growth profile of the company's ex-Copaxone franchises, which comprise c.80% of the company's intrinsic value and are growing at a 19% 5-year CAGR. We also see the potential for material upside from potential shareholder-friendly actions on the part of management. Actavis and Teva are our Buy-rated names within the multinational generic universe.”

Teva Pharmaceutical Industries Ltd. closed on Thursday at $40.32.

Latest Ratings for TEVA

DateFirmActionFromTo
Aug 2015Goldman SachsReinstatesBuy
Aug 2015JP MorganUpgradesNeutralOverweight
Jul 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Citigroup Liav AbrahamAnalyst Color Initiation Analyst Ratings

 

Related Articles (TEVA)

Get Benzinga's Newsletters